Bob's Discount Furniture is rated Buy, driven by robust unit growth, attractive store economics, and a compelling value pricing model. BOBS targets >500 stores by 2035, with mature stores delivering ~$9M AUV, >60% cash-on-cash returns by year two, and ~2-year payback. Value strategy underpins share gains: everyday prices ~10% below value competitors' lowest promotions and ~86% of orders in stock for rapid delivery.
Deutsche Bank to sell its India retail banking business to Kotak, advancing its Global Hausbank strategy and sharpening its focus on higher-growth businesses.
Denison Mines is rated Strong Buy, offering direct exposure to uranium's bullish supply-demand dynamics via its low-cost Canadian projects. DNN's flagship Wheeler River Project, with Phoenix Deposit construction commencing in Q2, targets production by mid-2028 and boasts industry-low all-in costs of $18.41/lb. With C$418 million in cash and limited equity issuance needs post-2028, DNN's balance sheet provides robust downside protection during market volatility.
Parker-Hannifin's Aerospace Systems gains from commercial and defense demand, with growth boosted by a planned aerospace acquisition.
3M gains from strong Safety & Industrial demand, lifting sales and margins, as 2026 guidance points to continued earnings growth.
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
RBC's Aerospace & Defense segment surges on commercial and defense demand, with a strong backlog supporting future growth.
GE Aerospace's Defense & Propulsion unit posts strong order and revenue growth, backed by major defense contracts and a robust project pipeline.
GE's Commercial Engines unit saw orders jump 93% to $17.3B as engine demand surged, while major investments aim to support future growth.
VOYA's unit launches two multi-manager alternative CITs for retirement plans, aiming to expand alternatives access and boost asset management growth.
EHC is expanding its rehabilitation network with a new 36-bed hospital in West Virginia.
U.S. drugmaker Eli Lilly has entered into an agreement to collaborate on and possibly licence experimental medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to around $3 billion if milestones are met, the Chinese drugmaker said Monday.